Chronic kidney disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• STAT3 1
• AKT 0
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• MAPK 0
• STING 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• JAK 0
• IL-1 1
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

14 of 14+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · K08

  Natural killer T cells in acute cardiorenal syndrome

  Oregon Health & Science University· Portland, United States· US$160,584 awarded in fiscal year 2026· until Jul 2031

• NIH NIDDK · R01

  The Interaction between Food Craving and Food Choice in Humans: A Computational Intracranial Electrophysiological Study

  Icahn School of Medicine at Mount Sinai· New York, United States· US$854,983 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  mRNA Splicing in Podocyte Biology and Glomerular Disease

  State University New York Stony Brook· Stony Brook, United States· US$755,725 awarded in fiscal year 2026· until Jun 2030

• NIH NIDDK · U01

  Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report

  Healthpartners Institute· Bloomington, United States· US$1,542,828 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,693,628· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, France· EU contribution €1,498,100· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, United Kingdom· EU contribution €325,435· until Feb 2029

10 of 1,529 running projects, newest first. Listed amounts together: US$840.6m + €145.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study

  NCT06094231· Department of Nephrology Clinic Ottakring Vienna· Updated 16 Apr 2026

  “Low number of participants”Registry text, quoted unchanged. Source

• Withdrawn

  Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease

  NCT04764097· Tan Tock Seng Hospital· Updated 21 Oct 2021

  “Lack of funding and similar competing study being conducted in Europe.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

  NCT07775846· Huijie Zhang· Source

• Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

  NCT07348484· Instituto de Investigación Biomédica de Salamanca· Source

• Improving Coronary Vascular Health in Women

  NCT06843902· Massachusetts General Hospital· Source

• Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis

  NCT07678203· Hospital Civil Juan I. Menchaca· Source

• A Study to Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

  NCT05884866· Klinikum Nürnberg· Source

• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

  NCT05390892· Brigham and Women's Hospital· Source

• Effect of Canagliflozin on Ultrafiltration & Fibrosis in Patients on Peritoneal Dialysis

  NCT06913647· McGill University Health Centre/Research Institute of the McGill University Health Centre· Source

• Dapagliflozin for Cardio-renal Protection After ICU Discharge

  NCT07025629· Assistance Publique - Hôpitaux de Paris· Source

• Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

  NCT06094920· University Medical Center Groningen· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 23
• Cohort Studies 556
• Genome-Wide Association Study 79

• Elevated glucose in kidney organoids induces tissue-intrinsic inflammation driving epithelial detachment.

  Stem Cell Reports, Sept 2026

• Podocyte injury damages podocytes in chimeric organoids.

  PLoS One, Aug 2026

• Modelling ischaemic AKI in human kidney organoids reveals injury-associated epithelial states and macrophage-epithelial crosstalk.

  Genome Med, Aug 2026

• Human Kidney Organoids to Uncover Preterm Birth-Associated Low Nephron Endowment.

  Nephron, May 2026

• Bridging Kidney Organoid Innovation and Regenerative Medicine: Current Advances and Future Directions.

  Cell Prolif, May 2026

• Induction of fibrosis in human kidney organoids delineates mechanisms and therapeutic targets of fibrotic kidney disease.

  Stem Cell Res Ther, Apr 2026

• Vascularization and maturation of kidney organoids: a comprehensive review of technological trends and challenges.

  J Artif Organs, Feb 2026

• Analysis of high glucose injury using human induced pluripotent stem cell-derived kidney organoids.

  BMC Nephrol, Jan 2026

• Splice modulation of COL4A5 reinstates collagen IV assembly in an organoid model of Alport syndrome.

  JCI Insight, Dec 2025

• Modeling kidney fibrosis and tubular regeneration in iPSC-derived kidney organoids.

  Stem Cell Res Ther, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.